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The 2005 Pfizer Medical Futures Forum brought together over 100 leading physician-
scientists to New York City to discuss the future of medicine and to select recipients 
of competitive grants in academic medical research and education. The Medical 
Futures Forum is the centerpiece event in Pfizer’s Medical and Academic Partnerships 
(MAP) program, which represents Pfizer’s commitment to advancing science and 
public health through grants to faculty members and academic institutions. This 
Forum session raised important, thought-provoking issues about Evidence-Based 
Medicine, such as how the evidence is summarized, and whether the evidence is 
used to make important policy decisions. 
 
Dr. Bryan Luce, Founder and Senior Research Leader at the MEDTAP Institute of 
United Biosource Corporation gave the keynote address. A panel of reactors to the 
talk included leaders from within Pfizer and academia, including Dr. Hugh Tilson, 
Senior Advisor to the Dean and Clinical Professor of Health Policy and Epidemiology 
at the University of North Carolina at Chapel Hill, Dr. Nicole Lurie, Senior Natural 
Scientist and Paul O’Neill, Alcoa Professor of Policy Analysis, RAND Corporation. 
Dr. Luce’s presentation was a follow-up to a recent article that he co-authored with 
Dr. Earl Steinberg, in Health Affairs, titled “Evidence Based? Caveat Emptor!” 
 
Dr. Luce’s talk, and the article that it was taken from, highlighted some of the 
serious problems with the ways that scientific evidence is both summarized and 
used, raising fundamental issues with Evidence-Based Medicine, that many in the 
academic and policy arenas take it as gospel.  Though it is clear that some 
treatments work better than others, or equally well, health plans and Medicare have 
been reluctant to make coverage and reimbursement decisions that are sensitive 
to these differences. For example, the Medicare Prescription Drug, Improvement, 
and Modernization Act (MMA) of 2003 precludes Medicare, in the event that two 
health care interventions are functionally equivalent, from “employing the 
commonsense notion that one should not purchase a product that is more costly 
than another product that is equivalent to it.”  Dr. Luce’s presentation, and the panel 
reactions, provoked the kind of spirited and insightful discussion that is the hallmark 
of the Pfizer’s Medical and Academic Partnerships (MAP) program. To read more 
about Pfizer’s MAP program, see http://www.promisingminds.com/. 
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